Search Medical Condition
Please enter condition
Please choose location

Burgos, Spain Clinical Trials

A listing of Burgos, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (27) clinical trials

Prospective Single-arm Multi Centre Observations Ultimaster Des Registry

All consecutive patients suitable for treatment with DES according to hospital routine practice in centres across the world that agree to participate in the e-ULTIMASTER registry will be treated with Ultimaster DES. Secondary objectives Evaluation of worldwide utilization of DES, Detection of rare events in representative patient population, identification of ...

Phase N/A

0.0 miles

Learn More »

Assessment of Ventricular Arrhythmia Risk After CRT-D Replacement for Patients With Primary Prevention Indication

The objective of this study is to describe, in a population of patients who had a primary prevention ICD indication at first implantation of a CRT-D, the relevance defibrillator back-up after the replacement of the first CRT-D. For that, the rate of patients with at least one sustained VTA detected ...

Phase N/A

0.0 miles

Learn More »

Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma

The primary trial objectives are: • Impact on progression-free survival (PFS) when adding MLN9708 to post-transplant maintenance treatment with lenalidomide/dexamethasone in patients with multiple myeloma. The secondary trial objectives are: - Evaluate development and clinical significance of minimal residual disease (MRD) from the time maintenance treatment is initiated, yearly over ...

Phase

0.0 miles

Learn More »

Observational Study of Obstructive Lung Disease (NOVELTY)

The NOVELTY study is a multi-country, multicentre, observational, prospective, longitudinal cohort study which will include patients with a physician diagnosis, or suspected diagnosis, of asthma and/or COPD. Patients will undergo clinical assessments and receive standard medical care as determined by the treating physician. All patients enrolled in the NOVELTY study ...

Phase N/A

0.0 miles

Learn More »

A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

This is an international, multicenter (study conducted at multiple sites) study designed to estimate remission rates and assess treatment response, tolerability, and patterns of use of Paliperidone Palmitate 3-Month Formulation (PP3M) in a diverse population of participants with schizophrenia. The study will consist of a screening phase (Day -7 to ...

Phase

0.0 miles

Learn More »

A Retrospective Observational Study to Assess the Impact of Co-morbidities on Treatment Response in Inflammatory Bowel Disease

This is a retrospective, non-interventional, observational study that will include consecutive participants diagnosed with Ulcerative Colitis (UC) or Crohn's Disease (CD) who started treatment with biologics between June 2011 and June 2013. This study will look at the impact of the co-morbidities on treatment response in IBD patients. The study ...

Phase N/A

0.0 miles

Learn More »

Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)

Study Design This will be an observational cohort study of patients with locally advanced or metastatic NSCLC (non-small cell lung cancer). Patients will be recruited from participating sites in Europe, Asia, and Canada. Patients meeting the study inclusion/exclusion criteria will be selected during a 24-month enrolment period per country and ...

Phase N/A

0.0 miles

Learn More »

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, is a prospective, randomized, double-blind, multicenter trial with the primary null hypothesis that, in patients with TIA or minor ischemic stroke treated with aspirin 50-325 mg/day, there is no difference in the event-free survival at 90 days in those ...

Phase

0.0 miles

Learn More »